{"product_id":"cloe-vrio-analysis","title":"Clover Leaf Capital Corp. (CLOE): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Clover Leaf Capital Corp. (CLOE)'s sustained success with this critical VRIO Analysis. We dissect its core capabilities - assessing their Value, Rarity, Inimitability, and Organization - to reveal precisely where its competitive edge lies and whether it can be maintained against rivals. Dive in now to see if these assets truly form an unassailable advantage!\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eClover Leaf Capital Corp. (CLOE) - VRIO Analysis: Sponsor’s Cannabis Industry Network (Yntegra Capital Management LLC)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core engine of Clover Leaf Capital Corp.’s original thesis: the network provided by its sponsor, Yntegra Capital Management LLC. Honestly, the situation has changed dramatically since the initial $138.3 million IPO in July 2021. The network was the key to sourcing deals in the cannabis space, but with the Board’s determination to liquidate following the merger termination in November 2024, that advantage is now moot.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on how that network stacked up against the VRIO criteria when the company was actively seeking a target:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eVRIO Dimension\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eAssessment\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eImplication for CLOE (Pre-Liquidation)\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eProvided crucial deal flow and industry connections for the cannabis mandate.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eModerate\u003c\/td\u003e\n    \u003ctd\u003eSpecific focus on compliant cannabis assets made it less common than generalist SPAC networks.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eModerate\u003c\/td\u003e\n    \u003ctd\u003ePersonal relationships are sticky, but the network's value was tied to the sponsor's current operational focus.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eHigh (Theoretically)\u003c\/td\u003e\n    \u003ctd\u003eSponsor control meant tight alignment, \u003cem\u003eif\u003c\/em\u003e the mandate was still active and a deal was being pursued.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eTemporary (Now Obsolete)\u003c\/td\u003e\n    \u003ctd\u003eValuable for deal sourcing, but the advantage dissolves when the company liquidates and redeems shares.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the current reality: the company is winding down. If onboarding takes 14+ days, churn risk rises - in this case, the risk is total dissolution. The sponsor’s ability to provide value is now focused on a clean wind-down, not deal execution.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eNetwork provided access to hard-to-find opportunities.\u003c\/li\u003e\n\u003cli\u003eSponsor, Yntegra Capital Investments, LLC, is an affiliate of Yntegra Capital Management LLC.\u003c\/li\u003e\n\u003cli\u003eThe company is now expected to redeem all outstanding Class A common stock.\u003c\/li\u003e\n\u003cli\u003eThe original focus was on cannabis industry businesses compliant with all laws.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft final redemption schedule for board review by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eClover Leaf Capital Corp. (CLOE) - VRIO Analysis: SPAC Shell and NASDAQ Listing Status (CLOE)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Offers a public listing vehicle, saving a target company significant time and cost for a direct listing.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitial Public Offering (IPO) Proceeds: \u003cstrong\u003e$138.31\u003c\/strong\u003e million.\u003c\/li\u003e\n\u003cli\u003eInitial Warrant Exercise Price: \u003cstrong\u003e$11.50\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eInitial Cash in Trust: Approximately \u003cstrong\u003e101.5%\u003c\/strong\u003e of IPO proceeds.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; many SPAC shells exist, but maintaining a NASDAQ listing is a baseline requirement.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitial Listing Exchange Target: The Nasdaq Capital Market.\u003c\/li\u003e\n\u003cli\u003eShares Outstanding (Ticker): \u003cstrong\u003e4.96M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIPO Date: July 20, 2021.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; the structure is standard, and the listing can be transferred or revoked.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCurrent Status: Determined to \u003cstrong\u003eliquidate\u003c\/strong\u003e the Company as of November 8, 2024.\u003c\/li\u003e\n\u003cli\u003ePrevious Merger Target: Kustom Entertainment, Inc.\u003c\/li\u003e\n\u003cli\u003eFinal Trading Status: Delisted to OTC and set to Position Closing Only (PCO).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the legal and administrative structure is in place for a potential transaction or liquidation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReported Market Capitalization: \u003cstrong\u003e$61.91M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFocus Industry: Legalized cannabis industry.\u003c\/li\u003e\n\u003cli\u003eCEO: Felipe MacLean.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None; this is a necessary commodity for a SPAC.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date Reference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIPO Proceeds\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$138.31M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHistorical IPO Figure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$61.91M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported Figure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.96M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTicker Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquidation Date Determined\u003c\/td\u003e\n\u003ctd\u003eNovember 8, 2024\u003c\/td\u003e\n\u003ctd\u003eAnnouncement Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Warrant Exercise Price\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.50\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProspectus Detail\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-Liquidation Status\u003c\/td\u003e\n\u003ctd\u003eOTC \/ Position Closing Only (PCO)\u003c\/td\u003e\n\u003ctd\u003eTrading Status\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eClover Leaf Capital Corp. (CLOE) - VRIO Analysis: Trust Value \/ Available Capital (Proxy: $138.3 Million IPO Trust)\n\u003c\/h2\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eRepresents the cash held in trust, which is the primary asset available for a business combination or return to shareholders. The initial gross proceeds from the Initial Public Offering were \u003cstrong\u003e$138,312,300\u003c\/strong\u003e. The Company announced its intention to liquidate on November 8, 2024, expecting to redeem all outstanding shares of Class A common stock sold in the IPO.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate; the absolute dollar amount is unique, but having a trust is standard for a SPAC. The initial trust value was based on the \u003cstrong\u003e$138,312,300\u003c\/strong\u003e raised in the July 2021 IPO, less any associated expenses and prior to any redemptions or extensions.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eHigh; the asset is cash held in a trust account, which is a standard, easily replicable structure for a Special Purpose Acquisition Company.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh; the funds are held by a third-party trustee, ensuring security and adherence to the trust agreement terms, including provisions for liquidation.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eNone; this is the baseline asset value for a SPAC shareholder, representing the potential return of invested capital.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eDate\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIPO Gross Proceeds\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$138,312,300\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJuly 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIPO Price Per Unit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJuly 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExtension Payment Deposited\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,383,123\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJuly 19, 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMerger Agreement Termination\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eNovember 7, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquidation Announcement\u003c\/td\u003e\n\u003ctd\u003eIntention to Redeem All Shares\u003c\/td\u003e\n\u003ctd\u003eNovember 8, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003eIPO Closing Date: July 20, 2021.\u003c\/li\u003e\n\u003cli\u003eInitial Public Offering Size: \u003cstrong\u003e13,831,230\u003c\/strong\u003e units.\u003c\/li\u003e\n\u003cli\u003eWarrant Exercise Price: \u003cstrong\u003e$11.50\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eExtension Payment represented \u003cstrong\u003e$0.10\u003c\/strong\u003e per public share.\u003c\/li\u003e\n\u003cli\u003eThe Company's securities are now trading on OTC under ticker \u003cstrong\u003eCLOE\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eClover Leaf Capital Corp. (CLOE) - VRIO Analysis: Sponsor’s Claimed “Insider” Insight into Cannabis Operations\n\u003c\/h2\u003e\n\u003ch\u003eSponsor’s Claimed “Insider” Insight into Cannabis Operations\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The sponsor claims a special insight into the market, which theoretically improves due diligence and valuation accuracy for a target.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many sponsors claim expertise, but verifiable, unique insight is rare.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; true, deep insight is hard to replicate without the sponsor’s specific history.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Low; this is an intangible asset tied to specific individuals, not a formal, scalable process.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; it only matters if a deal is actively being pursued.\u003c\/p\u003e\n\u003cp\u003eThe claimed insight is attributed to the Sponsor team, controlled by Yntegra Capital Management LLC, which has common ownership with companies including cannabis and real estate investments.\u003c\/p\u003e\n\u003cp\u003eKey executive experience supporting the claim includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFelipe MacLean: 15+ years experience building vertically integrated business.\u003c\/li\u003e\n\u003cli\u003eFelipe MacLean: Successfully profited from over $1 billion in commodities trading activity.\u003c\/li\u003e\n\u003cli\u003eFelipe MacLean: Recent placement of over $100MM in private equity investments.\u003c\/li\u003e\n\u003cli\u003eFelipe MacLean: Founder of Solace Holdings, with 20% market share in the leading vape category in Nevada.\u003c\/li\u003e\n\u003cli\u003eMr. Bjorkman: Served as Co-CEO of Solace Holdings from October 2017 to July 2020.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe SPAC's financial context as of its filing\/recent data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eSponsor\/Executive Experience Context\u003c\/td\u003e\n\u003ctd\u003eCLOE Financial\/Operational Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCannabis Operational Focus\u003c\/td\u003e\n\u003ctd\u003eSolace Holdings (THC \u0026amp; CBD company)\u003c\/td\u003e\n\u003ctd\u003eDoes not have significant operations.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRelevant Transaction Experience\u003c\/td\u003e\n\u003ctd\u003eOver $1 billion in commodities trading activity.\u003c\/td\u003e\n\u003ctd\u003eIPO Target: $125 million.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEntity Founding Year\u003c\/td\u003e\n\u003ctd\u003e2017 (Solace Holdings context).\u003c\/td\u003e\n\u003ctd\u003eFounded 2021.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Valuation\/Performance\u003c\/td\u003e\n\u003ctd\u003e20% market share in Nevada vape category.\u003c\/td\u003e\n\u003ctd\u003eMarket Cap: $61.91M; EPS (ttm): -0.21.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company's status contrasts with the sponsor's claimed operational background:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCLOE was incorporated in 2021.\u003c\/li\u003e\n\u003cli\u003eCLOE Net Income (ttm) was -$1.17M.\u003c\/li\u003e\n\u003cli\u003eCLOE Shares Outstanding: 4.96M.\u003c\/li\u003e\n\u003cli\u003eCLOE Stock Price (Sep 3, 2024): $11.68.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eClover Leaf Capital Corp. (CLOE) - VRIO Analysis: Sponsor’s Access to Advanced Facility Knowledge\n\u003c\/h2\u003e\n\u003cp\u003e\nThe analysis below focuses on the VRIO framework components as they relate to the sponsor's claimed access to advanced facility knowledge.\n\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003e\nThe sponsor's team includes the founder of Solace Holdings, a vertically integrated THC \u0026amp; CBD cannabis company, with leading brands in Nevada across all categories and 20% market share in the leading vape category. The founder has over 15+ years experience building vertically integrated business.\n\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003e\nProprietary operational knowledge is evidenced by the sponsor's claimed operation of 'one of the most technologically advanced facilities in the country.'\n\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003e\nThe operational know-how is associated with the sponsor's track record, including successful private equity investments and recent placement of over $100MM in private equity investments.\n\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003e\nThe asset is knowledge residing with the sponsor's team, controlled by Yntegra Capital Management LLC. The company's financial structure shows:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIPO Raised (Approximate Total)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$138.3 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIPO Units Priced\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e12,500,000\u003c\/strong\u003e units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares of Class A Common Stock per Unit (Implied)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Cap (Reported)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$163.79mil\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Cap (Alternative Report)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e61.91 Mil\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenues (Last 12 Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0 mil\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003e\nThe advantage is linked to the sponsor's specific background, which includes profiting from over $1 billion in commodities trading activity.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSponsor's CEO has 15+ years experience.\u003c\/li\u003e\n\u003cli\u003eSponsor's COO has experience with SHL Medical AG, a global solution provider in advanced drug delivery systems.\u003c\/li\u003e\n\u003cli\u003eThe company announced its intention to liquidate as of November 8, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eClover Leaf Capital Corp. (CLOE) - VRIO Analysis: Established Corporate Governance Framework\n\u003c\/h2\u003e\n\u003cp\u003eThe framework is evidenced by mandatory public disclosures and internal documentation.\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe existence of SEC filings, board charters, and established reporting lines provides a foundation for immediate compliance if a merger occurs.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAudit Committee Charter\u003c\/li\u003e\n\u003cli\u003eCompensation Committee Charter\u003c\/li\u003e\n\u003cli\u003eCode of Ethics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eLow; all listed companies must have this.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eHigh; these are standard regulatory requirements.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh; the structure is documented and ready for scrutiny.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Date\u003c\/th\u003e\n\u003cth\u003eReference Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares of Class A Common Stock Outstanding (as of 2024-08-15)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4,964,642\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Quarterly Report Filing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Units in Initial Public Offering (IPO)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,875,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSEC Registration Statement Filing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares of Class A Common Stock in IPO Units\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,875,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSEC Registration Statement Filing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Current Assets (as of 2024-06-30, in millions USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.12\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBalance Sheet Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets (as of 2024-06-30, in millions USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13.02\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBalance Sheet Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Liabilities (as of 2024-06-30, in millions USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23.83\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBalance Sheet Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShareholders' Equity (as of 2024-06-30, in millions USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-10.81\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBalance Sheet Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Redeemed from Trust Account (as of 2022-10-19)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12,204,072\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eForm 8-K Filing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmount Redeemed from Trust Account (as of 2022-10-19)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$125,587,180.34\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eForm 8-K Filing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eNone; it’s table stakes for being a public entity.\u003c\/p\u003e\n\u003cp\u003eThe company is classified as an 'emerging growth company' under federal securities laws, subject to reduced public company reporting requirements.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eClover Leaf Capital Corp. (CLOE) - VRIO Analysis: Historical Dividend Payout Mechanism (Jan 2025 Payout of $12.45)\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis focuses on the special capital return event executed by Clover Leaf Capital Corp. in January 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLatest Dividend Amount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.44989\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported latest dividend amount.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStated Annual Dividend\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.45\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported total annual dividend.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEx-Dividend Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJanuary 15, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThe date for entitlement to the dividend.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayout Period Type\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSpecial\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDesignation of the dividend payment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHistorical Dividend Yield (at event)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e115.17%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYield associated with the January 15, 2025 dividend.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Current Dividend Yield\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.00%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported current yield figure.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproximate Share Price (Reference)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.47\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eShare price around the time of data reporting.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe context of the event includes the following financial metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMarket Capitalisation: \u003cstrong\u003e$8.64m\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e52-week Share Price Range: \u003cstrong\u003e$12.00\u003c\/strong\u003e to \u003cstrong\u003e$12.49\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eReturn on Capital: \u003cstrong\u003e-24.73%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eReturn on Equity: \u003cstrong\u003e-21.74%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eVRIO Assessment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eValue: Demonstrates the ability to execute a significant capital return event, which builds trust with remaining shareholders.\u003c\/li\u003e\n\u003cli\u003eRarity: Low; capital returns are common, though the specific \u003cstrong\u003e115.17%\u003c\/strong\u003e yield mentioned is an anomaly compared to the reported current yield of \u003cstrong\u003e0.00%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eImitability: High; the mechanics of a distribution are well-understood.\u003c\/li\u003e\n\u003cli\u003eOrganization: Moderate; it shows the administrative process for capital movement works.\u003c\/li\u003e\n\u003cli\u003eCompetitive Advantage: None; it’s a transactional event, not a sustained advantage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eClover Leaf Capital Corp. (CLOE) - VRIO Analysis: Liquidation\/Redemption Execution Capability\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe ability to efficiently wind down operations and return capital to shareholders, minimizing administrative drag and legal risk.\u003c\/p\u003e\n\u003cp\u003eFinancial data relevant to the liquidation execution capability as of the latest reported period (TTM ending Jun 30, 2024) in Millions USD:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount (Millions USD)\u003c\/td\u003e\n\u003ctd\u003eShares Outstanding (Approx.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.05\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.02\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$23.83\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShareholders' Equity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$10.81\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Common Shares Outstanding (as of Aug 15, 2024)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4,964,642\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; many SPACs fail to execute clean liquidations.\u003c\/p\u003e\n\u003cp\u003eThe company announced its intention to liquidate following the termination of the Merger Agreement, effective November 7, 2024. The original Merger Agreement was dated June 1, 2023, and amended on June 24, 2024, and September 3, 2024.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMarket Capitalization at announcement: \u003cstrong\u003e$57.96M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFloat: \u003cstrong\u003e684.98k\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eHigh; the process is governed by trust agreements and SEC rules.\u003c\/p\u003e\n\u003cp\u003eThe liquidation process mandates the redemption of all outstanding shares of Class A common stock sold in the initial public offering.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eShares of Class A common stock outstanding as of August 15, 2024: \u003cstrong\u003e4,964,642\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eBook Value Per Share as of Jun 30, 2024: \u003cstrong\u003e-$2.03\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh; this is the current, mandated operational focus.\u003c\/p\u003e\n\u003cp\u003eThe Board of Directors determined to liquidate the Company upon termination of the merger agreement.\u003c\/p\u003e\n\u003cp\u003eFinancial structure details as of TTM ending Jun 30, 2024:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiability\/Equity Component\u003c\/td\u003e\n\u003ctd\u003eAmount (Millions USD)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Current Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.02\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOther Long-Term Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.82\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommon Stock\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetained Earnings\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$10.81\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eNone; it’s a necessary end-of-life function.\u003c\/p\u003e\n\u003cp\u003eThe company expects to announce additional information on the redemption process in the coming days following the November 8, 2024 announcement.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eClover Leaf Capital Corp. (CLOE) - VRIO Analysis: Management Team’s SPAC Experience\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eManagement Team’s SPAC Experience\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The collective experience of the officers and directors in navigating the SPAC lifecycle, from IPO to potential combination or liquidation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePresident and CEO Felipe MacLean has over \u003cstrong\u003e15+ years\u003c\/strong\u003e of experience, including successfully profiting from over \u003cstrong\u003e$1 billion\u003c\/strong\u003e in commodities trading activity and recent placement of over \u003cstrong\u003e$100MM\u003c\/strong\u003e in private equity investments.\u003c\/li\u003e\n\u003cli\u003eCOO Markus Puusepp has held roles including Chief Strategy Officer of SHL Medical AG since 2017 and spent over seven years in private equity and medtech in Hong Kong and Beijing.\u003c\/li\u003e\n\u003cli\u003eThe initial trust account held \u003cstrong\u003e$125.0 million\u003c\/strong\u003e or potentially \u003cstrong\u003e$143.75 million\u003c\/strong\u003e following the full exercise of the underwriters’ over-allotment option from the offering at \u003cstrong\u003e$10.00\u003c\/strong\u003e per unit.\u003c\/li\u003e\n\u003cli\u003eAs of a recent report, the Market Cap is \u003cstrong\u003e$61.91 million\u003c\/strong\u003e with \u003cstrong\u003e4.96 million\u003c\/strong\u003e shares outstanding.\u003c\/li\u003e\n\u003cli\u003eThe Company announced its intention to liquidate on November 8, 2024, following the termination of the merger agreement with Kustom Entertainment, Inc.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; experienced SPAC teams are sought after, but this team’s success is mixed.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe team successfully navigated the S-4 effectiveness for the Kustom Entertainment combination on August 5, 2024, but subsequently terminated the agreement on November 7, 2024, leading to a liquidation decision.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; deep experience is hard to buy off the shelf.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; the team is in place, but their current motivation is key.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Board determined to liquidate the Company as of November 8, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the value is realized only in the successful completion of the next phase, whatever it may be.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe immediate next phase is the expected redemption of all outstanding Class A common stock from the trust account upon liquidation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e Draft the final trust value reconciliation statement for the Q4 2025 filing by next Wednesday.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eManagement Team Experience Metrics\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eFelipe MacLean (CEO)\u003c\/td\u003e\n\u003ctd\u003eMarkus Puusepp (COO)\u003c\/td\u003e\n\u003ctd\u003eCLOE Trust Account (Initial)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommodities Trading Success\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e$1 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate Equity Placement Success\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e$100MM\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eExperience in Hong Kong\/Beijing\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRelevant Industry Focus\u003c\/td\u003e\n\u003ctd\u003eCannabis (Solace Holdings Founder)\u003c\/td\u003e\n\u003ctd\u003eMedTech\/Consulting\u003c\/td\u003e\n\u003ctd\u003eCannabis Industry Target\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Public Offering Trust Value\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$125.0 million\u003c\/strong\u003e to \u003cstrong\u003e$143.75 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCLOE Financial Snapshot (Latest Reported Data)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMarket Capitalization: \u003cstrong\u003e$61.91M\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eShares Outstanding: \u003cstrong\u003e4.96 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCurrent Ratio: \u003cstrong\u003e0.02\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuick Ratio: \u003cstrong\u003e0.01\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash Position: \u003cstrong\u003e$51,117\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal Debt: \u003cstrong\u003e$4.66 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNet Cash Position (Per Share): \u003cstrong\u003e-$0.93\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eLast Earnings Date: March 21, 2025\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516138578069,"sku":"cloe-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/cloe-vrio-analysis.png?v=1740161018","url":"https:\/\/dcf-model.com\/es\/products\/cloe-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}